Stoke Therapeutics Inc. (STOK)
Stoke Therapeutics Statistics
Share Statistics
Stoke Therapeutics has 54.08M shares outstanding. The number of shares has increased by 1.62% in one year.
| Shares Outstanding | 54.08M |
| Shares Change (YoY) | 1.62% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 40.86M |
| Failed to Deliver (FTD) Shares | 49.45K |
| FTD / Avg. Volume | 5.74% |
Short Selling Information
The latest short interest is 8.75M, so 16.52% of the outstanding shares have been sold short.
| Short Interest | 8.75M |
| Short % of Shares Out | 16.52% |
| Short % of Float | 20.32% |
| Short Ratio (days to cover) | 9.5 |
Valuation Ratios
The PE ratio is -6.69 and the forward PE ratio is -4.11. Stoke Therapeutics's PEG ratio is 0.22.
| PE Ratio | -6.69 |
| Forward PE | -4.11 |
| PS Ratio | 16.3 |
| Forward PS | 1.5 |
| PB Ratio | 2.6 |
| P/FCF Ratio | -6.84 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Stoke Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.81 |
| Quick Ratio | 5.81 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $285.59K |
| Profits Per Employee | $-695.16K |
| Employee Count | 128 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.37% in the last 52 weeks. The beta is 0.98, so Stoke Therapeutics's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -52.37% |
| 50-Day Moving Average | 9.17 |
| 200-Day Moving Average | 12.1 |
| Relative Strength Index (RSI) | 27.25 |
| Average Volume (20 Days) | 862.07K |
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 36.55M and earned -88.98M in profits. Earnings per share was -1.65.
| Revenue | 36.55M |
| Gross Profit | 36.55M |
| Operating Income | -101.37M |
| Net Income | -88.98M |
| EBITDA | -101.37M |
| EBIT | -101.37M |
| Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has 127.98M in cash and 2.32M in debt, giving a net cash position of 125.66M.
| Cash & Cash Equivalents | 127.98M |
| Total Debt | 2.32M |
| Net Cash | 125.66M |
| Retained Earnings | -490.83M |
| Total Assets | 271.56M |
| Working Capital | 192.7M |
Cash Flow
In the last 12 months, operating cash flow was -86.85M and capital expenditures -203K, giving a free cash flow of -87.05M.
| Operating Cash Flow | -86.85M |
| Capital Expenditures | -203K |
| Free Cash Flow | -87.05M |
| FCF Per Share | -1.61 |
Margins
Gross margin is 100%, with operating and profit margins of -277.31% and -243.42%.
| Gross Margin | 100% |
| Operating Margin | -277.31% |
| Pretax Margin | -243.42% |
| Profit Margin | -243.42% |
| EBITDA Margin | -277.31% |
| EBIT Margin | -277.31% |
| FCF Margin | -238.15% |
Dividends & Yields
STOK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for STOK is $21, which is 237.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $21 |
| Price Target Difference | 237.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 3 |